Integrated clinical experience with ONC201 in H3 K27M glioma.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.2059
Abstract: 2059Background: ONC201 is a DRD2 antagonist in Phase II trials for cancers that exhibit dysregulation of the dopamine pathway. We previously reported an objective response in the first recurrent H3 K27M midline glioma patient who… read more here.
Keywords: glioma; onc201 k27m; k27m glioma; clinical experience ... See more keywords